Form 4 for CRL Charles River Laboratories
Accepted 2022-05-31 00:00:00 ET · period of report 2022-05-27 · accession 0001127602-22-016064 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-31 | 2022-05-28+ | CRL | Girshick Birgit | COO, Corp. Executive VP | F - Tax | $244.41 | -368 | 35.8K | -1% | -$89.9K |
| D | 2022-05-31 | 2022-05-27 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $0.00 | +2,455 | 36.1K | +7% | $0 |
| D | 2022-05-31 | 2022-05-27 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $244.41 | +6,634 | 6,634 | New | +$1.62M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-28 | F | D | 150 | $244.41 | 35,974 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-27 | A | A | 2,455 | $0.00 | 36,124 | D | — | — | (F1) Unvested restricted stock units vest as follows: 613 on May 27, 2023, 614 on May 27, 2024, 614 on May 27, 2025 and 614 on May 27, 2026. |
| 3 | Common | Common Stock | 2022-05-29 | F | D | 218 | $244.41 | 35,756 | D | — | — | |
| 4 | Derivative | Stock Options (Right to Buy) | 2022-05-27 | A | A | 6,634 | $244.41 | 6,634 | D | $244.41 · 2023-05-27 to 2032-05-27 | 6,634 Common Stock | (F2) Stock Options vest as follows: 1,658 on May 27, 2023, 1,659 on May 27, 2024, 1,658 on May 27, 2025 and 1,659 on May 27, 2026. |